By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Cost of Injection Jumps from $15 to $1,500
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Health Reform > Cost of Injection Jumps from $15 to $1,500
BusinessHealth Reform

Cost of Injection Jumps from $15 to $1,500

JohnCGoodman
JohnCGoodman
Share
2 Min Read
SHARE

The following is from an AP story. See also Merrill Goozner’s comments here.

A drug for high-risk pregnant women has cost about $10 to $20 per injection. Next week, the price shoots up to $1,500 a dose, meaning the total cost during a pregnancy could be as much as $30,000.

That’s because the drug, a form of progesterone given as a weekly shot, has been made cheaply for years, mixed in special pharmacies that custom-compound treatments that are not federally approved ….. But recently, KV Pharmaceutical of suburban St.Louis won government approval to exclusively sell the drug, known as Makena (Mah-KEE’-Nah). ….. The cost is justified to avoid the mental and physical disabilities that can come with very premature births, said KV Pharmaceutical chief executive Gregory J. Divis Jr. The cost of care for a preemie is estimated at $51,000 in the first year alone.To get FDA approval, the company is spending hundreds of millions of dollars in additional research, including an international study involving 1,700 women, Divis said. The FDA last month signed off and gave Makena orphan drug status. That designation ensures Ther-Rx will be the sole source of the drug for seven years.

More Read

TEDMED Day #1, Light on Medicine, High on Inspiration
HIMSS14: Bullish on Growth in the International Healthcare IT Market
Can Regional TEDMED Communities Cultivate and Implement Healthcare Innovation?
Know It or Not, the Competition is Drinking Your Milkshake
Why Massachusetts Can Afford Universal Health Insurance

Last month, KV sent cease-and-desist letters to compounding pharmacies, telling them they could face FDA enforcement actions if they kept making the drug.

TAGGED:health care businesshealth care reform
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

woman in pink long sleeve shirt sitting on gray couch
Understanding Divorce Law and the Role of Attorneys in Family Disputes
Policy & Law
January 14, 2026
Redefining Romance: How Care and Presence Are Showing as Big Gestures
lifestyle
January 9, 2026
dental check up
What to Expect From Your First Visit to a Dentist
Dental health
January 9, 2026
foot and vein health
The Hidden Connection Between Foot and Vascular Health
Health
January 8, 2026

You Might also Like

Ebola Education, Hospital Marketing, Healthcare Marketing, Healthcare Communication
BusinessGlobal HealthcareHospital AdministrationNewsPublic Health

Hospital Marketing and Ebola: Communication and Education Needed

October 30, 2014

Are There Differences in Medicare Spending Across States?

March 30, 2011
pharmaphorum social media
BusinessPolicy & LawSocial Media

Is Social Media Worth the Risk for Pharma?

March 2, 2015
Clinical Trial Marketing, Clinical Trial Participation, Clinical Trial Recruitment
Business

Why Patients Drop Out of Clinical Trials and What Marketers Can Do About It

November 27, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Go to mobile version
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?